Net profit of Astrazeneca Pharma India declined 26.62% to Rs 38.43 crore in the quarter ended September 2024 as against Rs 52.37 crore during the previous quarter ended September 2023. Sales rose 31.16% to Rs 408.00 crore in the quarter ended September 2024 as against Rs 311.07 crore during the previous quarter ended September 2023.
| Particulars | Quarter Ended |
| Sep. 2024 | Sep. 2023 | % Var. |
| Sales | 408.00 | 311.07 | 31 |
| OPM % | 12.88 | 16.96 | - |
| PBDT | 60.35 | 60.63 | 0 |
| PBT | 51.03 | 56.95 | -10 |
| NP | 38.43 | 52.37 | -27 |